GT101

BIOLOGICAL2 trials

Sponsors

Grit Biotechnology

Conditions

AdultSolid Tumors, Adult

Early Phase 1

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

TerminatedNCT06077903

Grit BiotechnologyAdult

Start: 2021-07-05End: 2025-12-30Updated: 2026-05-05

Phase 1

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

RecruitingNCT05430373

Grit BiotechnologySolid Tumors, Adult

Start: 2022-05-23End: 2026-12-30Target: 31Updated: 2026-09-14

Related Papers

GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.

Journal of Clinical Oncology2026-05-27

GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.

Journal of Clinical Oncology2025-05-281 citations

Phase 1 study of GT101 as an autologous tumor infiltrating lymphocyte (TIL) therapy in advanced solid tumors.

Journal of Clinical Oncology2024-06-01